Recently galactosyltransferase has been noted as a new tumor marker. In this report galactosyltransferase activity was measured in sera of various diseases including malignant tumors and the levels of the enzyme activities were compared. The levels of the enzyme were higher in sera of malignant tumors and liver diseases than those in sera of other diseases. In malignant tumors little organ specificity was found with respect to the levels of galactosyltransferase activities. The levels of the enzyme were considered to have no relation to carcinoembryonic antigen or a feto protein. On the other hand, in liver diseases the levels of the enzyme were correlated to the severity of liver damage. Therefore, it is reasonable to presume that the elevation of serum galactosyltransferase activity is caused chiefly by malignant tumors and liver damage.
Galactosyltransferase
activity has been reported to be present on the intracellular and cell surface membranes of various cell types1),2).
Recently Podolsky was able to detect a cancerspecific isoenzyme of galactosyltransferase in sera of cancer patients by means of discontinuous polyacrylamide gel electrophoresis3. Galactosyltransferase activities in sera of other diseases, however, have not been studied thoroughly, we studied the activities of this enzyme in sera of various diseases in this paper.
Methods and Materials
Galactosyltransferase activity was measured by the method of Kim4). Glycoprotein acceptor in this study was fetuin minus terminal sialic acid and penultimate galactose residues. The acceptor was prepared as described by Spiro5'.
Fetuin (500 mg; Gibco, Grand Island, N.Y., USA) was suspended in 25 ml of 0. In this report we measured the levels galactosyltransferase activities in sera of various diseases and the data were compared each other.
In our results the levels of galactosyltransferase activities in malignant tumors and in liver cirrhosis were significantly higher than those in other various diseases. No significant difference was found between the levels of the enzyme in malignant tumors and those in liver cirrhosis.
In malignant tumors the levels in primary and metastatic liver cancer were slightly higher than those in malignant tumors without liver involvement.
But the difference was not significant.
Among all groups of malignant tumors superiority of the levels of the enzyme was not noted in malignant tumors of any specific organ.
Thus, organ specificity in the level of galactosyltransferase activitiy was not considered to be present in malignant tumors. On the other hand, the levels of the enzyme in liver cirrhosis were significantly higher than those in chronic hepatitis.
In these chronic liver diseases the level of the enzyme was proportional to the 
